Avidity Biosciences, Inc. RNA
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Janus Henderson Group PLC London, X014.5MShares$1.03 Billion0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$936 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY11.4MShares$805 Million6.62% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$713 Million0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.79MShares$693 Million0.05% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.64MShares$612 Million6.47% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$610 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.65MShares$541 Million4.55% of portfolio
-
State Street Corp Boston, MA4.89MShares$346 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.86MShares$202 Million0.01% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,373
-2.52%
|
$170,856
$72.23 P/Share
|
|
Jan 07
2026
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,373
-6.11%
|
$170,856
$72.23 P/Share
|
|
Jan 07
2026
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,974
-3.0%
|
$142,128
$72.23 P/Share
|
|
Jan 07
2026
|
John B Moriarty Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,374
-3.09%
|
$170,928
$72.23 P/Share
|
|
Jan 07
2026
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,965
-1.65%
|
$141,480
$72.23 P/Share
|
|
Jan 07
2026
|
Charles Calderaro Iii Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,727
-6.96%
|
$268,344
$72.23 P/Share
|
|
Jan 07
2026
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
8,576
-2.94%
|
$617,472
$72.23 P/Share
|
|
Dec 19
2025
|
Arthur A Levin Director |
SELL
Bona fide gift
|
Direct |
1,330
-6.77%
|
-
|
|
Dec 18
2025
|
Sarah Boyce President and CEO |
SELL
Bona fide gift
|
Direct |
29,159
-9.08%
|
-
|
|
Dec 17
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,695
-12.72%
|
$972,345
$71.87 P/Share
|
|
Dec 17
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+20.34%
|
-
|
|
Dec 17
2025
|
Charles Calderaro Iii Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,726
-15.38%
|
$690,546
$71.87 P/Share
|
|
Dec 17
2025
|
Charles Calderaro Iii Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,250
+26.88%
|
-
|
|
Dec 17
2025
|
John B Moriarty Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,824
-25.85%
|
$1,904,504
$71.87 P/Share
|
|
Dec 17
2025
|
John B Moriarty Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,000
+35.05%
|
-
|
|
Dec 17
2025
|
Sarah Boyce President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,742
-4.67%
|
$1,117,682
$71.87 P/Share
|
|
Dec 17
2025
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+8.43%
|
-
|
|
Dec 17
2025
|
Eric Mosbrooker Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
47,990
-20.71%
|
$3,407,290
$71.87 P/Share
|
|
Dec 17
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,000
+36.18%
|
-
|
|
Dec 17
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,298
-12.71%
|
$1,228,158
$71.87 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 374K shares |
|---|---|
| Exercise of conversion of derivative security | 556K shares |
| Payment of exercise price or tax liability | 173K shares |
|---|---|
| Open market or private sale | 840K shares |
| Bona fide gift | 30.5K shares |